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Piriprost and nordihydroguiaretic acid (NDGA), specific inhibitors of arachidonate lipoxygenase, inhibited phytohaemagglutinin (PHA)-stimulated 
breakdown of inositol lipids in human T lymphocytes. The dual inhibitors eicosatetraynoic acid (ETYA) and BW 75X, which inhibit both lipoxy- 
genase and cyclooxygenase, also had similar actions, whereas indomethacin and acetylsalicyclic acid, which inhibit cyclooxygenase alone, did not. 
The effects of lipoxygenase inhibitors and dual inhibitors were reversible. These agents did not inhibit phosphatidylinositol-4,5-bisphosphate-specific 
phospholipase C (PIP,-PLC) in vitro. Bromophenacyl bromide, and irreversible inhibitor of phospholipase 4, also abolished PHA-stimulated 
inositol lipid breakdown without affecting PIP,-PLC in vitro. The results are consistent with a role for the PHA-stimulated generation of arachi- 
donic acid and its conversion to lipoxygenase metabolites (e.g. leukotrienes and/or hydroxyeicosatetraenoic acids) as intermediate steps in the signal 
transduction pathway between cell-surface mitogen receptors and the stimulation of PIP,-PLC in lymphocytes. 
Lymphocyte transformation; Second messenger; Phosphatidylinositol; Phospholipase C; Lipoxygenase 
1. INTRODUCTION 
The cleavage of phosphatidylinositol-4,5-bisphos- 
phate (PIP2) by a specific phospholipase C (PLC) and 
the subsequent generation of the second messengers 
diacylglycerol (DAG) and inositol-1,4,5trisphosphate 
(IP3) is thought to play a crucial role in the transduc- 
tion of mitogenic signals following the binding of 
mitogens such as phytohaemagglutinin (PHA) or 
specific monoclonal antibodies to cell-surface struc- 
tures on T lymphocytes [ 1,2]. DAG stimulates protein 
kinase C whereas IP3 mediates elevation of cellular 
Ca2+ concentrations [3]. Cascades of biochemical pro- 
cesses consequent to these early events eventually 
synergize in securing commitment of the lymphocyte to 
mitosis [4]. 
The mechanisms which link the binding of mitogens 
to cell-surface structures and the stimulation of 
PIP2-PLC are unclear. Considerable evidence supports 
a role for guanine nucleotide-binding proteins (G pro- 
teins) in coupling receptor stimulation to the activation 
of polyphosphoinositide breakdown in several bio- 
logical systems [5] including lymphocytes [6-81. 
However, reconstitution experiments using purified G 
proteins and PIP2-PLC have not been carried out. 
Therefore, it is unclear whether a G protein is the only 
mediator linking receptors to PIP2-PLC. Since there is 
some evidence that G proteins may activate phospho- 
lipase A2 [9], the enzyme which generates free 
arachidonic acid from phospholipids, we asked 
whether metabolites of arachidonic acid may in turn 
stimulate PIPz-PLC following PHA stimulation of T 
lymphocytes. The results here show that two inhibitors 
of arachidonic acid lipoxygenase and two drugs which 
inhibit both lipoxygenase and cyclooxygenase nzymes 
impair the stimulation of T lymphocyte PIP2-PLC by 
PHA. By contrast, two agents which inhibit cycloox- 
ygenase (but not lipoxygenase) did not impair this pro- 
cess. The data suggest that the generation of 
arachidonic acid and its metabolism to leukotrienes or 
hydroxyeicosatetraenoic acids (HETEs) [lo] may be an 
obligatory step in the coupling of T lymphocyte 
mitogen receptors to PIP2 breakdown. 
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2. MATERIALS AND METHODS 
2.1. Materials 
Abbreviations: PIPz, phosphatidylinositol-4,5-bisphosphate; PLC, Piriprost was a gift from Upjohn Co., Kalamazoo, MI, and 
phospholipase C; DAG, diacylglycerol; IPs, inositol-1,4,5-trisphos- BW 755C from Wellcome Research Laboratories, Beckenham, Kent. 
phate; PHA, phytohaemagglutinin; HETE, hydroxyeicosatetraenoic Eicosatetraynoic acid (ETYA) was purchased from Cayman 
acid; ETYA, eicosatetraynoic acid; NDGA, nordihydroguiaretic Chemicals and nordihydroguiaretic acid (NDGA), indomethacin and 
acid; PLAz, phospholipase AZ acetylsalicylic acid were from Sigma Chemical Co., Poole, Dorset. 
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[2-3H]Myo-inositol and [‘H]PIPz were supplied by Amersham Inter- 
national, England. 
2.2. Cells 
Lymphocytes were prepared from freshly drawn peripheral blood 
from healthy volunteers by sedimentation on Lymphoprep 
(Nyegaard, Oslo) gradients and essentially freed of monocytes as 
described [ll]. They were cultured in inositol-free RPM1 1640 
medium supplemented with 10% dialyzed fetal calf serum [12]. 
2.3. Assay for PHA-stimulated inositol lipid breakdown 
Lymphocytes were labelled overnight with 5 FCi. ml-’ [2-3H]myo- 
inositol. The cells were washed twice in Hanks’ salts, and resuspend- 
ed (at l-5 x IO6 ml-‘) in RPM1 1640 medium supplemented with 
10% fetal calf serum. LiCl was added to 10 mM and the cells in- 
cubated at 37°C for 20 min. PHA (Wellcome) was added to 
10 /l.ml-’ and the incubation continued for a further 30 min. 
Water-soluble compounds were extracted as described [13] and 
radiolabel in inositol phosphates was quantitated by chromatography 
on Dowex Al-X8 columns [14]. 
2.4. Assay for PIPz-PLC 
Lymphocytes were lysed by hypotonic shock and resolved into par- 
ticulate and cytosolic fractions following the removal of nuclei [15]. 
PIPz-PLC was assayed by incubating 10 pg of protein with 50 pmol 
[3H]PIPz in 40 ~1 reactions containing 20 mM Tris-HCI, pH 7.5 and 
either 400 nM (particulate fractions) or 150 nM (cytosolic fractions) 
free Ca*+ (buffered with EGTA). The release of radiolabelled IPs was 
quantitated after 5 min incubation at 37°C as described [16]. 
3. RESULTS AND DISCUSSION 
Piriprost and NDGA, two inhibitors of lipoxygenase 
[ 17,181, both abolished the PHA-stimulated generation 
of labelled inositol phosphates in lymphocytes whose 
inositol lipids were prelabelled with [3H]inositol (fig.1). 
The response to each drug was clearly dose-dependent. 
ETYA and BW 755C, dual inhibitors which inhibit 
both lipoxygenase and cyclooxygenase [17] also in- 
hibited PHA-stimulated inositol lipid breakdown in a 
dose-responsive manner (fig.1). However, in- 
domethacin, which inhibits cyclooxygenase but not 
lipoxygenase [ 171 did not affect PHA-stimulated 
generation of inositol phosphates (fig.2). Similar 
results were obtained using another cyclooxygenase in- 
hibitor, acetylsalicylic acid (not shown). We therefore 
conclude that the abolition of inositol lipid breakdown 
by the dual inhibitors ETYA and BW 755C cannot be 
attributed to their effects on cyclooxygenase, and is 
more likely the result of their actions on the lipox- 
ygenase pathway. Additionally, the results obtained 
with the dual inhibitors ETYA and BW 755C show that 
the effect of inhibiting the lipoxygenase pathway is not 
attributable to the increased metabolism of 
arachidonate via the cyclooxygenase pathway, with the 
consequent generation of prostaglandins, which may in 
turn inhibit inositol lipid breakdown via generation of 
cyclic AMP and activation of cyclic AMP-dependent 
protein kinase [ 19,201. 
The effects of the lipoxygenase inhibitors on inositol 
lipid breakdown were not attributable to irreversible 
damage to cellular structure. The effect of 100 ,uM 
piriprost was immediately reversed by washing and 
resuspension of the cells (fig.3). However, the effect of 
higher concentrations of the drug were only partially 
reversed. Similar results were obtained using ETYA 
(not shown). 
We then considered the possibility that the lipox- 
ygenase inhibitors may directly affect PIP2-PLC. Table 
1 shows that lymphocytes contain both membrane- 
bound and cytosolic forms of PIP2-PLC which could 
be assayed in vitro using [3H]PIP2 as a substrate in the 
presence of Ca2+ ion buffered in the nanomolar range. 
Even at the highest levels of NDGA, ETYA or piriprost 
used in the intact cell experiments (fig.1) only a 
marginal inhibition of PIP2-PLC was observed in vitro 
(table 1). Similar results were obtained using BW 755C 
in a separate xperiment (not shown). These results also 
suggest hat the effects of the drugs on inositol lipid 
breakdown in intact cells could not be attributed to the 
perturbation of Ca2+ levels, since the in vitro 
PIP2-PLC assay is critically dependent on nanomolar 
levels of Ca”. As a control, 100 pM neomycin sulfate, 
a known inhibitor of PIPz-PLC, was shown to inhibit 
the in vitro assay almost completely (table 1). 
Taken together, the data suggest that piriprost, 
NDGA, ETYA and BW 755C reversibly inhibit a 
regulatory process which links the binding of PHA to 
cell-surface structures on lymphocytes to the stimula- 
tion of PIP?-PLC. We propose that the observed ef- 
fects may be explained by a requirement for the 
generation of lipoxygenase metabolites as an in- 
termediate step in the coupling process. While it re- 
mains theoretically possible that each of these 4 drugs 
affects a target other than lipoxygenase, which is 
critical in the coupling process, this is unlikely given 
their widely differing chemical structures. Piriprost is a 
derivative of prostaglandin I (6,9-(deepoxy)d,P(phe- 
nylimino)-A6,*-prostaglandin Ii), whereas NDGA 
(4,4’ -(2,3-dimethyl- 1,4-butanediyl)-bis-(1,2-benzenedi- 
01) contains catechol residues. The dual inhibitors BW 
755C (3-amino-1-(3-trifluoromethylphenyl)-2-pyrazo- 
line HCl) and the arachidonic acid analogue ETYA (a 
competitive inhibitor of lipoxygenase and cyclooxy- 
genase) also have widely differing structures. We also 
wish to stress that although the I& values observed for 
each drug (fig. 1) appear to be higher than those found 
for inhibition of lipoxygenase in phosphate-buffered 
saline [ 171, we and others [18] have observed that these 
drugs bind tightly to serum proteins and that their ef- 
fective free concentrations may be as much as lo-fold 
lower than the concentrations added. Since the ex- 
periments described here were carried out in serum- 
containing medium (necessary for maintaining cell 
viability during [‘Hlinositol labelling and subsequent 
manipulations), the effective I& of the inhibitors are 
probably of the order of lo-fold less than is apparent 
from fig. 1. 
In many systems the rate-determining step in the pro- 
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Fig. 1. PHA-stimulated generation of [3H]inositol phosphates (vertical axis) by [‘Hlinositol-labelled lymphocytes treated for 1 h with the indicated 
concentrations (horizontal axis) of 4 different lipoxygenase inhibitors. In each experiment the PHA-stimulated increase in [sH]inositol phosphates 
in the absence of drugs was 4-6-fold over basal levels. The results in each panel are typical of at least 5 separate xperiments. 1.5 x ld ceils 
per determination were used in the experiment using piriprost, and 5 x lo6 cells for each of the other titrations. 
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Fig.2. PHA-stimulated generation of [“Hlinositol phosphates 
(vertical axis) in lymphocytes treated for 1 h with the indicated 
concentrations (horizontal axis) of indomethacin. The results are 
typical of 3 experiments. 
duction of lipoxygenase metabolites is the generation of 
arachidonic acid by the cleavage of phospholipids by 
phospholipase A2 (PLAz). We therefore tested the ef- 
fects of bromophenacy1 bromide, an irreversible in- 
hibitor of PLAz [21] on the PHA-stimulated generation 
of inositol phosphates. Fig.4 shows that as little as 
1 PM of this inhibitor reduced mitogen-stimulated in- 
ositol lipid breakdown by 500/o. However, the precise 
specificities of bromophenacyl bromide are unknown. 
Although this inhibitor also did not affect PIP;?-PLC in 
vitro (table 1), the conclusion that the action described 
here depends on its inhibition of PLAt must remain 
tentative until more specific inhibitors become 
available. (We were unable to use steroids or mepacrine 
as PLAz inhibitors because the former are toxic to lym- 
phocytes whereas mepacrine inhibits PIPz-PLC in 
vitro.) 
The data presented here support the hypothesis that 
lymphocyte mitogens such as PHA trigger the genera- 
tion of arachidonic acid which is then converted to a 
86 
Volume 258, number 1 FEBS LETTERS November 1989 
pM Piriprost 
Fig.3. [‘H]Inositol pre-labelled lymphocytes were incubated for 1 h 
with the indicated concentrations (horizontal axis) of piriprost, and 
the PHA-stimulated generation of [3H]inositol phosphates (vertical 
axis) was measured (solid lines). One-half of each culture was washed 
free of the drug immediately before the addition of PHA (broken 
lines). 
lipoxygenase product(s), and that this product 
stimulates PIP2-PLC in turn. Stable products of lipox- 
ygenase include the leukotrienes and the hydrox- 
yeicosatetraenoic acids (HETEs) [lo]. Several actions 
of exogenous leukotrienes on lymphocytes have been 
documented [22] and lipoxygenase inhibitors have been 
shown to suppress the synthesis of the lymphokine 
interleukin-2 by T leukaemia cells [23]. Mitogenic ef- 
fects of leukotrienes have also been described in other 
systems [24], and leukotriene D4 has been shown to 
stimulate inositol lipid hydrolysis in rat basophilic 
leukaemia cells [25]. The generation of lipoxygenase 
Table 1 
The effect of lipoxygenase inhibitors and bromophenacyl bromide on 
lymphocyte PIP*-PLC activity in vitro 
Additions to assay PIPI-PLC activitya 
(fmol IP3 released/5 min/bg protein) 
Cytosolic 
PLC 
Membrane-bound 
PLC 
None 
70 /M NDGA 
50 CM ETYA 
200 CM piriprost 
15 ,uM bromophenacyl 
bromide 
100 FM neomycin sulphate 
830 868 
761 800 
867 806 
909 735 
869 804 
< 10 22 
a PIPz-PLC was assayed as described in section 2 
100 
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Fig.4. PHA-stimulated generation of [3H]inositol phosphates by 
lymphocytes treated with the indicated concentrations of 
bromophenacyl bromide for 1 h. 
products following mitogen-stimulation of T lym- 
phocytes is a controversial issue (e.g. [26,27]). 
However, by pre-labelling of highly purified T lym- 
phocytes with [3H]arachidonic acid we have repeatedly 
observed that PHA stimulates the dose-dependent 
generation of a metabolite, tentatively identified as 
5-HETE (Ayub Khan, M., Jeremy, J.Y., A.V.H. and 
R.G.W., in preparation). This metabolite is not 
liberated from the cells and may therefore have escaped 
detection in previous studies, many of which employed 
radioimmunoassay procedures. Furthermore, the 
PHA-stimulated generation of this metabolite was in- 
hibited by NDGA with a dose-response similar to the 
effect of this drug on inositol lipid breakdown. These 
observations extend our earlier tentative conclusions 
that PHA treatment of lymphocytes stimulated PLA2 
activity as judged by the accumulation of 
glycerophosphoinositol [7]. 
It would be of interest to determine whether the 
putative role of lipoxygenase metabolites proposed here 
is restricted to lymphocytes or is a general feature of 
other growth factor signalling pathways as well. 
However, whereas many growth factors trigger very 
rapid generation of IP3 (i.e. within seconds) [28], pro- 
duction of this second messenger in mitogen stimulated 
lymphocytes is delayed by about 10 min, suggesting 
that (an)other event(s) precede the breakdown of in- 
ositol lipids in this system [29], in accord with the 
observations reported here. 
We are currently attempting to elucidate the 
mechanism by which a putative arachidonate 
metabolite may stimulate PIP2-PLC during the 
mitogenic response of T lymphocytes. It will be of par- 
ticular interest to localize the site(s) of action of the G 
proteins involved in stimulation of lymphocyte 
PIP2-PLC [6-81 with respect o the mechanism propos- 
ed here. 
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